Cymabay Therapeutics

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Metabolys

This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.

Intercept Pharmaceuticals

This company develops and commercialises small molecule therapeutics to treat chronic liver diseases for healthcare providers and patients.

GenKyoTex

This biopharmaceutical company develops selective NOX inhibitors to treat patients with chronic inflammatory and fibrotic diseases such as primary biliary cholangitis.

Bluejay Therapeutics

The company develops monoclonal antibody therapies and small molecule drugs to treat patients with chronic hepatitis B, hepatitis D and other liver diseases.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.

SFA Theraputics

This biopharmaceutical company develops oral small-molecule drugs for patients suffering from autoimmune diseases, chronic inflammatory conditions, and various types of liver cancer.